Genomics & Informatics

Korea Genome Organization (한국유전체학회)
권호 표지
DOI QR코드

DOI QR Code

Reflections on the US FDA's Warning on Direct-to-Consumer Genetic Testing

  • Yim, Seon-Hee (Department of Medical Education, Integrated Research Center for Genome Polymorphism, MRC, College of Medicine, The Catholic University of Korea) ;
  • Chung, Yeun-Jun (Department of Microbiology, Integrated Research Center for Genome Polymorphism, MRC, College of Medicine, The Catholic University of Korea)
  • Received : 2014.05.14
  • Accepted : 2014.11.05
  • Published : 2014.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

In November 2013, the US Food and Drug Administration (FDA) sent a warning letter to 23andMe, Inc. and ordered the company to discontinue marketing of the 23andMe Personal Genome Service (PGS) until it receives FDA marketing authorization for the device. The FDA considers the PGS as an unclassified medical device, which requires premarket approval or de novo classification. Opponents of the FDA's action expressed their concerns, saying that the FDA is overcautious and paternalistic, which violates consumers' rights and might stifle the consumer genomics field itself, and insisted that the agency should not restrict direct-to-consumer (DTC) genomic testing without empirical evidence of harm. Proponents support the agency's action as protection of consumers from potentially invalid and almost useless information. This action was also significant, since it reflected the FDA's attitude towards medical application of next-generation sequencing techniques. In this review, we followed up on the FDA-23andMe incident and evaluated the problems and prospects for DTC genetic testing.

Keywords

References

  1. US Food and Drug Administration. Warning letter, Nov 22, 2013. Silver Spring: US Food and Drug Administration, 2013. Accessed 2014 Oct 31. Available from: http://www.fda.gov/iceci/enforcementactions/warningletters/2013/ucm376296.htm.
  2. The FDA and me. Nature 2013;504:7-8.
  3. Green RC, Farahany NA. Regulation: the FDA is overcautious on consumer genomics. Nature 2014;505:286-287. https://doi.org/10.1038/505286a
  4. Lee KL, Lee SM. Market Analysis and Strategies for Regulatory Reform in Medical Industry. Public-Private Joint Regulation Advancement Initiative, 2014.
  5. Su P. Direct-to-consumer genetic testing: a comprehensive view. Yale J Biol Med 2013;86:359-365.
  6. iSpot.tv. 23 and Me (TV commercial). Bellevue: iSpot.tv, 2013. Accessed 2014 Nov 1. Available from: http://www.ispot.tv/ad/7qoF/23-and-me.
  7. Wojcicki A. Just the facts, please. Nat Biotechnol 2013;31:1075-1076. https://doi.org/10.1038/nbt.2771
  8. Hogarth S, Javitt G, Melzer D. The current landscape for direct- to-consumer genetic testing: legal, ethical, and policy issues. Annu Rev Genomics Hum Genet 2008;9:161-182. https://doi.org/10.1146/annurev.genom.9.081307.164319
  9. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009;106:9362-9367. https://doi.org/10.1073/pnas.0903103106
  10. American College of Medicine Genetics Board of Directors. ACMG statement on direct-to-consumer genetic testing. Genet Med 2004;6:60.
  11. Hudson K, Javitt G, Burke W, Byers P; American Society of Human Genetics Social Issues Committee. ASHG Statement* on direct-to-consumer genetic testing in the United States. Obstet Gynecol 2007;110:1392-1395. https://doi.org/10.1097/01.AOG.0000292086.98514.8b
  12. US Centers for Disease Control and Prevention. Genomic testing: ACCE model process for evaluating genetic tests. Atlanta: US Centers for Disease Control and Prevention, 2010. Accessed 2014 Nov 1. Available from: http://www.cdc.gov/genomics/gtesting/ACCE/.
  13. 23andMe. FDA update: December 5th. Palo Alto: 23andMe, 2013. Accessed 2014 Nov 1. Available from: https://customercare.23andme.com/entries/23273619-FDAUpdate-December-23273615th.
  14. US Food and Drug Administration. Close out letter, March 25, 2014. Silver Spring: US Food and Drug Administration, 2014. Accessed 2014 Nov 1. Available from: http://www.fda.gov/ICECI/EnforcementActions/WarningLetters/ucm391016.htm.
  15. TechFreedom. FDA: Don't ban marketing of home genomics kits like 23andMe. Change.org, 2014. Accessed 2014 Nov 1. Available from: https://www.change.org/petitions/fda-dont-ban-marketing-of-home-genomics-kits-like-23andme.
  16. O'Connor L. 23andMe faces $5 million lawsuit days after being banned by FDA. The Huffington Post, 2013. Accessed 2014 Nov 1. Available from: http://www.huffingtonpost.com/2013/2012/2004/2023andme-lawsuit_n_4387699.html.
  17. CBS News. 23andMe personalized DNA test seeks FDA approval. New York: CBS Interactive Inc., 2012. Accessed 2014 Nov 1. Available from: http://www.cbsnews.com/news/23andme-personalized-dna-test-seeks-fda-approval/.
  18. CBC News. 23andMe genetic testing service raises ethical questions. New York: CBS Interactive Inc., 2014. Accessed 2014 Nov 1. Available from: http://www.cbc.ca/news/business/23andme-genetic-testing-service-raises-ethical-questions-1.2785522.
  19. Downing NS, Ross JS. Innovation, risk, and patient empowerment: the FDA-mandated withdrawal of 23andMe's Personal Genome Service. JAMA 2014;311:793-794. https://doi.org/10.1001/jama.2014.148
  20. Zettler PJ, Sherkow JS, Greely HT. 23andMe, the Food and Drug Administration, and the future of genetic testing. JAMA Intern Med 2014;174:493-494. https://doi.org/10.1001/jamainternmed.2013.14706
  21. US Food and Drug Administration. FDA allows marketing of four "next generation" gene sequencing devices. Silver Spring: US Food and Drug Administration, 2013. Accessed 2014 Nov 1. Available from: http://www.fda.gov/newsevents/newsroom/pressannouncements/ucm375742.htm.

Cited by

  1. Awareness, attitudes and perspectives of direct-to-consumer genetic testing in Greece: a survey of potential consumers vol.60, pp.9, 2015, https://doi.org/10.1038/jhg.2015.58
  2. Diet and exercise changes following direct-to-consumer personal genomic testing vol.10, pp.1, 2017, https://doi.org/10.1186/s12920-017-0258-1
  3. Making Meaningful Clinical Use of Biomarkers vol.12, pp.1177-2719, 2017, https://doi.org/10.1177/1177271917715236
  4. Third party interpretation of raw genetic data: an ethical exploration vol.25, pp.11, 2017, https://doi.org/10.1038/ejhg.2017.126
  5. Direct to consumer genetic testing and the libertarian right to test vol.44, pp.11, 2018, https://doi.org/10.1136/medethics-2016-103778